Abstract
Ethical issues in the field of schizophrenia research have become a focus of intense debate in the past year. The publication of the final report of the National Bioethics Advisory Commission (NBAC) coupled with recent media reports have catapulted these issues into international view. Major questions have been raised about the capacity of individuals with mental illness to consent to participation in research studies and about the conflicts of interest that psychiatric researchers experience. Questions have also been raised about whether it is ethical to ask patients with schizophrenia to participate in studies that can be expected to lead to an increase in psychotic symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Whitaker R, Kong D: Doing harm: research on the mentally ill, in Boston Globe. 1998: Boston. p. A1. This four part investigative report catalogues all of the major accusations of ethical wrongdoing in psychiatric research.
National Bioethics Advisory Commission: Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Rockville, MD: 1998. The 21 recommendations of the NBAC are described and discussed in detail. The introductory chapters provide an excellent background for understanding the Commission’s recommendations.
Marshall, E: Panel tightens rules on mental disorders. Science 1998, 282:1617.
Michels, R: Are research ethics bad for our mental health? N Engl J Med 1999, 340(18):1427–1430. An articulate and thoughtful critique of the NBAC report.
Capron, AM: Ethical and human-rights issues in research on mental disorders that may affect decision-making capacity. N Engl J Med 1999, 340(18):1430–1434.
American Psychiatric Association: Guidelines for Assessing the Decision-Making Capacities of Potential Research Subjects with Cognitive Impairment. Am J Psych 1998, 155(11):1649–1650.
Zipursky RB, Darby P: Placebo-controlled studies in schizophrenia —ethical and scientific perspectives: an overview of conference proceedings. Schizophr Res 1999, 35:189–190. Whether placebo controls should be used in studies of schizophrenia requires an understanding of ethics, scientific methodology, decisionmaking capacity and schizophrenia research. Issues raised in these domains are reviewed in the context of the debate on the ethics of placebo-controlled trials.
Rothman KJ, Michels KB: The continued unethical use of placebo controls. N Engl J Med 1994, 331(6):394–398.
Declaration of Helsinki IV, World Medical Association, 41st World Medical Assembly, Hong Kong, September 1989, in In The Nazi doctors and the Nuremberg Code: human rights in human experimentation. Edited by Annas GJ, Grodin MA. New York: Oxford University Press; 1989:339-342.
Lasagna L: The Helsinki Declaration: timeless guide or irrelevant anachronism. J Clin Psychopharmacol 1995, 15(2):96–98.
Streiner DL: Placebo-controlled trials: when are they needed? Schizophrenia Research 1999, 35:201–210.
Weijer C: Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary? Schizophr Res 1999, 35:211–218.
Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 1987, 317:141–145.
Placebo-controlled studies in schizophrenia: ethical and scientific perspectives. Panel Discussion. Schizophr Res 1999, 35:227-236.
Carpenter WT, Conley RR: Sense and nonsense: an essay on schizophrenia research ethics. Schizophr Res 1999, 35:219–225.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zipursky, R.B. Ethical issues in schizophrenia research. Curr Psychiatry Rep 1, 13–19 (1999). https://doi.org/10.1007/s11920-999-0005-1
Issue Date:
DOI: https://doi.org/10.1007/s11920-999-0005-1